Posted

Latest Results from End-Ischemic HOPE U.S. Randomized Clinical Trial for Liver Transplantation Show Safety, Reduced Early Allograft Dysfunction, and Shorter Hospital Stays with HOPE

Chicago, June 4, 2024 – Bridge to Life Ltd, a leading provider of organ preservation solutions, has announced the latest findings from the Bridge to HOPE clinical trial, utilizing the VitaSmart [...]

Posted

Bridge to Life Announces Late-Breaker, Oral and Poster Presentations on Bridge to HOPE trial with VitaSmart at 2024 American Transplant Congress (ATC) in Philadelphia, PA, June 1-5, 2024

Chicago, May 8, 2024   Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of four abstracts based on data from its U.S. pivotal clinical [...]

Posted

Meta-Analysis of Data from Trials of Machine Perfusion Technologies in Liver Transplantation Demonstrates Clinical Advantages of Hypothermic Oxygenated Machine Perfusion (HOPE), according to Bridge to Life Ltd.

Results of late-breaker Cochrane review and meta-analysis confirmed significant improvement in several parameters with HOPE compared to static cold storage and normothermic machine perfusion [...]

Posted

Two Independent Studies Representing Largest Real-World Experience with Hypothermic Oxygenated Machine Perfusion (HOPE) Reinforce Significant Benefits in Liver Preservation Before Transplantation, according to Bridge to Life Ltd.

Portuguese study confirms use of HOPE provides demonstrably improved liver graft utilization with reduced rates of non-anastomatic biliary stricture (NAS); Italian study demonstrates increasing [...]

Posted

Bridge to Life Announces Abstract Presentations at The 2024 International Congress of the International Liver Transplantation Society (ILTS) in Houston, Texas, May 1-4, 2024

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of five accepted abstracts, including a late-breaker, at the 2024 International [...]

Posted

Bridge to Life Announces Abstract Presentations at The European Society for Transplantation’s ELITA Summit 2024 in Madrid, Spain, April 18-20, 2024

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The [...]

Posted

Bridge to Life Reintroduces EasiSlush® to the US Market, Meeting High Demand for Easy-to-Use Sterile Slush for Organ Transplantation

Bridge to Life Ltd, a leading provider of organ preservation solutions, today announces the return of EasiSlush™ to the US market, effective immediately. With its unmatched ease of use, high [...]

Posted

Bridge to Life Achieves ISO 13485:2016 Certification, Reinforcing Commitment to Quality and Safety in Hypothermic Oxygenated Perfusion and Cold Flush Organ Preservation Solutions

Bridge to Life Ltd, a renowned market leader in cold flush organ preservation solutions, is proud to announce its recent certification for ISO 13485:2016. This achievement further solidifies the [...]

Posted

Bridge to Life Statement on KSE Recall

Earlier this week Bridge to Life (BTL) became aware of the distribution of a recall notice from Krackeler Southeast Scientific LLC (KSE which was acquired by ILC Dover) to OPO’s. BTL wanted to [...]

Posted

Bridge to Life Divests Certain Assets to TransMedics

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle [...]

page 1 of 2